Zacks
Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth
📊
AI Sentiment
Positive
6/10
- Home
- ALNY
as of 02-11-2026 3:58pm EST
$322.02
$0.96
-0.30%
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 52.9B | IPO Year: | 2004 |
| Target Price: | $474.42 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 27 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $205.87 - $495.55 | Next Earning Date: | 02-12-2026 |
| Revenue: | $3,210,070,000 | Revenue Growth: | 53.24% |
| Revenue Growth (this year): | 70.4% | Revenue Growth (next year): | 44.32% |
| P/E Ratio: | 979.16 | Index: | N/A |
| Free Cash Flow: | 221.4M | FCF Growth: | +1278.10% |
AI-Powered ALNY Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 69.03%
69.03%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Alnylam Pharmaceuticals Inc. (ALNY)
Fitzgerald Kevin Joseph
Sell
CSO & EVP, Head of Research
ALNY Jan 13, 2026
Avg Cost/Share
$370.80
Shares
2,290
Total Value
$848,064.62
Owned After
21,386
Fitzgerald Kevin Joseph
Sell
CSO & EVP, Head of Research
ALNY Jan 12, 2026
Avg Cost/Share
$364.80
Shares
1,510
Total Value
$547,927.38
Owned After
21,386
Greenstreet Yvonne
Sell
Chief Executive Officer
ALNY Jan 12, 2026
Avg Cost/Share
$364.80
Shares
9,577
Total Value
$3,475,156.51
Owned After
84,307
Garg Pushkal
Sell
EVP Chief R&D
ALNY Jan 12, 2026
Avg Cost/Share
$364.80
Shares
1,510
Total Value
$547,928.97
Owned After
22,526
Tanguler Tolga
Sell
EVP, Chief Commercial Officer
ALNY Jan 12, 2026
Avg Cost/Share
$364.80
Shares
1,510
Total Value
$547,927.38
Owned After
30,657
Poulton Jeffrey V.
Sell
EVP, Chief Financial Officer
ALNY Jan 12, 2026
Avg Cost/Share
$364.80
Shares
2,780
Total Value
$1,008,765.87
Owned After
57,465
Fitzgerald Kevin Joseph
Sell
CSO & EVP, Head of Research
ALNY Nov 17, 2025
Avg Cost/Share
$456.70
Shares
12,128
Total Value
$5,483,989.61
Owned After
21,386
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Fitzgerald Kevin Joseph | ALNY | CSO & EVP, Head of Research | Jan 13, 2026 | Sell | $370.80 | 2,290 | $848,064.62 | 21,386 | |
| Fitzgerald Kevin Joseph | ALNY | CSO & EVP, Head of Research | Jan 12, 2026 | Sell | $364.80 | 1,510 | $547,927.38 | 21,386 | |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Jan 12, 2026 | Sell | $364.80 | 9,577 | $3,475,156.51 | 84,307 | |
| Garg Pushkal | ALNY | EVP Chief R&D | Jan 12, 2026 | Sell | $364.80 | 1,510 | $547,928.97 | 22,526 | |
| Tanguler Tolga | ALNY | EVP, Chief Commercial Officer | Jan 12, 2026 | Sell | $364.80 | 1,510 | $547,927.38 | 30,657 | |
| Poulton Jeffrey V. | ALNY | EVP, Chief Financial Officer | Jan 12, 2026 | Sell | $364.80 | 2,780 | $1,008,765.87 | 57,465 | |
| Fitzgerald Kevin Joseph | ALNY | CSO & EVP, Head of Research | Nov 17, 2025 | Sell | $456.70 | 12,128 | $5,483,989.61 | 21,386 |
Latest Alnylam Pharmaceuticals Inc. News
ALNY Breaking Stock News: Dive into ALNY Ticker-Specific Updates for Smart Investing
Zacks
Countdown to Alnylam (ALNY) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Does Alnylam Pharmaceuticals (NASDAQ:ALNY) Have A Healthy Balance Sheet?
📊
AI Sentiment
Positive
7/10
Zacks
Do Options Traders Know Something About Alnylam Pharmaceuticals Stock We Don't?
âž–
AI Sentiment
Neutral
5/10
Simply Wall St.
3 Stocks Estimated To Be Trading At Discounts Of Up To 49.2%
📈
AI Sentiment
Highly Positive
9/10
Zacks
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy?
âž–
AI Sentiment
Neutral
5/10
Simply Wall St.
Discounted Value Stocks With Estimated Upside In February 2026
📈
AI Sentiment
Highly Positive
8/10
Compare ALNY vs Leading Stocks
See how ALNY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ALNY Alnylam Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.